Saturday, August 23, 2025

MindMed Sees Positive Results For Its LSD Treatment For Anxiety Disorders Published In Peer-Reviewed Journal

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Thursday that the previously released positive topline data related to its clinical trial evaluating lysergic acid diethylamide (LSD) in the treatment of anxiety disorders has been published in a peer-reviewed scientific journal Biological Psychiatry.

“This paper further reinforces the positive preliminary evidence for LSD in patients who suffer from anxiety disorders,” said CEO Rob Barrow. “These results are encouraging and supportive of our proprietary MM-120 product candidate in its potential to one day offer a therapeutic benefit for patients suffering from GAD [Generalized Anxiety Disorder] after just a single-dose administration.”

The positive results of the trial were first released in May 2022, presented by the biotech firm’s collaborators Prof. Matthias Liechti and Dr. Friederike Holze at University Hospital Basel in London’s PSYCH Symposium.

Topline data showed a 65% clinical response in subjects treated with LSD while there’s only 9% clinical response in the placebo subjects. Further, effects were optimal after 2 weeks and were sustained up to 16 weeks.

Barrow added that phase 2b trial for MM-120 is ongoing and the firm believes the drug candidate “has a highly attractive commercial opportunity given its potential benefits for GAD patients.”

The firm’s share price has been gradually declining, falling 61% year-to-date on the Nasdaq. After trading consistently under the US$1.00 minimum bid requirement by the exchange, the firm finally completed the proposed 15-to-1 reverse split on August 29.

Mind Medicine Inc. last traded at $12.10 on the NEO.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

A Medical Breakthrough the Market Overlooked | David Elsley – Cardiol Therapeutics

Why Grade Beats Size in Silver Mining | Frank Basa – Nord Precious Metals

Are Investors Missing the Start of the Next Commodity Supercycle? | Morgan Lekstrom – NexMetals

Recommended

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

ESGold Signs MOU For Tailings Project In Colombia With Grades Up To 42 g/t Gold, 280 g/t Silver

Related News

Canaccord Reiterates $1.75 Price Target For Mind Medicine Following Roadshow Event

This morning, Canaccord released a flash update for Mind Medicine (NEO: MMED) with highlights from...

Monday, September 28, 2020, 11:02:24 AM

Shroom Progress! MindMed Advances Towards a Phase 2 LSD Microdosing Trial For Adult ADHD

Aftermarket MindMed (NEO:MMED) announced they entered into a clinical trial agreement with Maastricht University to...

Monday, May 11, 2020, 10:29:04 PM

MindMed Concludes Phase 1 Clinical Trial Of Psychedelic Derivative Drug For Opioid Use Disorder

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, has recently concluded the phase...

Tuesday, January 4, 2022, 10:29:00 AM

Mind Medicine Pays JR Rahn $6.7 Million In Shares To Leave Leadership Roles

It seems that after selling $24.7 million in company stock, JR Rahn is looking to...

Wednesday, June 9, 2021, 07:50:06 AM

Mind Medicine: Canaccord Genuity Initiates Coverage With C$1.75 Price Target

Yesterday, Canaccord initiated coverage on Mind Medicine (NEO: MMED) with a Speculative Buy rating and...

Wednesday, September 16, 2020, 04:15:00 PM